Hologic, Inc. (NASDAQ:HOLX) CEO Stephen P. Macmillan Sells 3,672 Shares

Hologic, Inc. (NASDAQ:HOLX) CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $0.45 during trading on Friday, hitting $78.11. 1,660,472 shares of the company traded hands, compared to its average volume of 1,628,747. The stock has a market capitalization of $18.23 billion, a price-to-earnings ratio of 39.67, a PEG ratio of 2.63 and a beta of 0.99. The business’s fifty day moving average is $74.20 and its 200-day moving average is $74.74. Hologic, Inc. has a one year low of $64.02 and a one year high of $82.45. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $0.98 by $0.05. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business’s revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 earnings per share. As a group, equities analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Evercore ISI cut their price target on Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 2nd. JPMorgan Chase & Co. boosted their price objective on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Hedge Funds Weigh In On Hologic

Several hedge funds and other institutional investors have recently made changes to their positions in HOLX. BKM Wealth Management LLC acquired a new position in shares of Hologic during the fourth quarter worth approximately $86,000. McGuire Investment Group LLC boosted its position in shares of Hologic by 0.3% during the fourth quarter. McGuire Investment Group LLC now owns 139,161 shares of the medical equipment provider’s stock worth $9,943,000 after buying an additional 366 shares during the period. Yarbrough Capital LLC acquired a new position in shares of Hologic during the fourth quarter worth approximately $355,000. Raymond James & Associates boosted its position in shares of Hologic by 9.9% during the fourth quarter. Raymond James & Associates now owns 276,880 shares of the medical equipment provider’s stock worth $19,783,000 after buying an additional 24,867 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Hologic by 9.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 925,968 shares of the medical equipment provider’s stock worth $66,160,000 after buying an additional 80,475 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.